Figure 3

Effect of neutralising anti-PDGF antibody on cell viability of malignant glioma cells. (A) Inhibition of cell viability in malignant glioma cells following the treatment with anti-PDGF antibody. Tumour cells (U87-MG, D54, and T98G) and fibroblast MRC5 cells were seeded at 5 × 10³ cells well⁻¹ (0.1 ml) in 96-well flat-bottomed plates and incubated overnight at 37°C. After exposure to anti-PDGF or control antibody (1 μg ml⁻¹) for 1–3 days, the cells were trypsinised and the number of viable cells was counted. The viability of the cells treated with control antibody was regarded as 100%. Results shown are the means±s.d. of three independent experiments. ^*P<0.05, ^**P<0.02. (B) Effect of extrinsic activation or inactivation of Akt on cell viability. U87-MG cells were treated with anti-PDGF antibody or control antibody in the presence of recombinant active Akt (50 ng) or adenovirus-mediated dominant-negative Akt (20 MOI) for 3 days. Results shown are the means±s.d. of three independent experiments. ^*P<0.02, ^**P<0.05.